{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".21","upperLimit":".56","value":".38"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Evaluated using RECIST version 1.0. Confirmed tumor response rate was defined as achieving partial response (PR) or complete response (CR) in two consecutive assessments at least 6 weeks apart. CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. The confirmed response rate is reported as the number of participants with confirmed responses divided by the number of evaluated participants.","dispersionType":"95% Confidence Interval","groups":[{"description":"Group 1 (6/6 UGT1A1 genotype):\n\nPatients receive 150 mg/m\\^2 irinotecan hydrochloride IV over 90 minutes and 100 mg/m\\^2 oxaliplatin IV over 2 hours on day 1. Patients also receive 1600 mg/m\\^2/day capecitabine PO BID on days 2-15\n\nGroup 2 (6/7 UGT1A1 genotype):\n\nPatients receive 150 mg/m\\^2 irinotecan hydrochloride IV over 90 minutes and 85 mg/m\\^2 oxaliplatin IV over 2 hours on day 1. Patients also receive 400 mg/m\\^2/day capecitabine PO BID on days 2-15.\n\nGroup 3 (7/7 UGT1A1 genotype):\n\nPatients receive 75 mg/m\\^2 irinotecan hydrochloride IV over 90 minutes and 85 mg/m\\^2 oxaliplatin IV over 2 hours on day 1. Patients also receive 400 mg/m\\^2/day capecitabine PO BID on days 2-15","id":"OG000","title":"All Patients (6/6, 6/7, 7/7 UGT1A1 Genotype)"}],"paramType":"NUMBER","populationDescription":"One patient was later found to be a major treatment violation during cycle 1 and was not included in this analysis. All the other 32 patients were analyzed together for this endpoint.","reportingStatus":"POSTED","timeFrame":"36 weeks","title":"Confirmed Tumor Response Rate (Proportion of Participants With Complete Response)","type":"PRIMARY","unitOfMeasure":"proportion of patients"}